Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service. A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Subscribe

Title Date published
Do We Have Good Evidence For New Drugs? My Denmark Lectures (Sept 2023) 1 Of 3 2023-10-04
Great And Crazy Things We Do In Medicine 2023-09-20
Fixing Cancer Medicine w/ Timothee Olivier 2023-09-12
Coumadin, ECMO, RCTs and more 2023-09-11
Prasad and Mandrola discuss recent journal articles/ Republicans/ Stenting 2023-08-23
Placebo/ Journal Errors/ Cancer Screening w/ Mandrola - SM crossover 2023-07-10
Testosterone/ Should Scientists Debate/ Mike Joyner 2023-06-28
Post Protocol Therapy - QOL - Adjuvant - Olivier Joins VP 2023-06-10
ADAURA OS RESULTS - THE TRIAL WAS UNETHICAL 2023-06-08
OBS studies vs RCTs - Trial Emulation - RCT Duplicate - We debate recent JAMA Paper 2023-05-17
Myeloma Roundtable - Manni M. Raj C. VP discuss controversies 2023-05-13
Mammographic Screening : A complete review of the evidence 2023-05-11
The Crushing, Cruel Cost of Cancer Drugs - My Lecture 2023-04-29
Sensible Med Crossover - Cifu/ Mandrola/ Prasad & Wallensky 2023-04-24
Cochrane Mask Debates - Jefferson/ Heneghan/ Prasad 2023-04-15
Zeb Jamrozik - Vaccine errors/ Sweden/ Equipoise & Science itself 2023-04-12
Harvard-MIT Center for Reg. Science Lecture (4-4-23) - Dubious FDA drug Approvals 2023-04-05
5.47 - Real World Evidence - Keynote Lecture in Denmark 2023-03-26
5.46 - What is Science: reflections on the field 2023-03-10
5.45 - Bar Karmma - Karmma 3 | Idacel vs 'standard care 2023-03-07
1234567891011121314151617181920

Comments about Plenary Session - inactive due to federal service

comments powered by Disqus
Advertisment: